[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microsatellite-stable-mss-colorectal-cancer-crc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microsatellite-stable-mss-colorectal-cancer-crc":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100648959","phase-3-folfiri-plus-bevacizuamb-and-ql1706-in-second-line-treatment-for-mcrc-100648959",false,"NCT07729605","FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC","FOLFIRI Plus Bevacizuamb With or Without Iparomlimab and Tuvonralimab as Second-Line Treatment for Metastatic Colorectal Cancer: A Randomized Controlled Trial","FIRBIT","Inclusion Criteria:\n\n* 1\\. Willing and able to provide written informed consent. 2. Age ≥ 18 years old. 3.Histologically confirmed metastatic colorectal adenocarcinoma with pMMR\u002FMSS status. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 5.Discontinued first-line oxaliplatin-based doublet chemotherapy for metastatic colorectal cancer due to intolerable toxicities or disease progression; OR developed recurrent metastatic disease within 6 months after the last dose of adjuvant chemotherapy. 6.Presence of evaluable lesions on imaging examinations. 7. Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment. 8.Willing and able to comply with study procedures and scheduled visit schedules\n\nExclusion Criteria:\n\n* 1.Patients complicated with digestive tract diseases including duodenal ulcer, ulcerative colitis, intestinal obstruction, or other conditions judged by the investigator to potentially cause gastrointestinal hemorrhage or perforation; or massive pleural effusion or ascites requiring intervention. 2.Previous or concurrent cancer that is distinct in primary site or histology from colon cancer within 5 years prior to randomization. 3. Radiological evidence of brain metastases. 4. Prior treatment with irinotecan hydrochloride, or prior receipt of PD-1 and\u002For CTLA-4 immunotherapy in the first-line setting. 5. Autoimmune diseases requiring continuous systemic steroid therapy. 6. History of laparotomy, thoracotomy or intestinal resection within 28 days prior to enrollment; or unhealed wounds (excluding suture wounds from central venous catheter implantation), gastrointestinal ulcers or traumatic fractures. 7. Any of the following events occurring within 12 months before study enrollment: myocardial infarction, severe\u002Funstable angina pectoris, New York Heart Association (NYHA) class ≥ 2 cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure. 8.Confirmed human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related diseases. 9. Active inflammatory bowel disease or other colorectal diseases causing chronic diarrhea; interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes mellitus, hypertension, pulmonary fibrosis, acute pneumonia, etc.). 10. Breastfeeding or pregnant women; lack of effective contraceptive. 11. Other severe physical or psychiatric illnesses, or laboratory abnormalities that may increase the risks of study participation or interfere with study outcomes; or patients deemed unsuitable for this study by the investigator.","ALL","18 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Thsi study is a randomised, parallel-controlled phase II\u002FIII trial evaluating FOLFIRI plus bevacizumab with or without QL1706 as second-line therapy for metastatic colorectal cancer. The primary endpoint is PFS. Secondary endpoint includes overall survival, objective response rate, safety profiles, immune-related adverse events, and patient quality of life. Exploratory analyses focus on dynamic shifts in tumour immune microenvironment and biomarkers, aiming to identify predictive signatures for therapeutic efficacy and immune toxicities.",[27,28],"Colorectal Cancer Metastatic","Microsatellite Stable (MSS) Colorectal Cancer (CRC)",[30,31,32,33,34],"PD-1\u002FCTLA-4","QL1706","Bevacizumab","FOLFIRI","Second-line","NOT_YET_RECRUITING","2026-07-22",{"date":38,"type":39},"2026-07-27","ACTUAL",{"date":41,"type":21},"2026-07-30",{"date":43,"type":21},"2029-07-30",{"name":45,"class":46},"Sun Yat-sen University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100580275","phase-2-sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer-100580275","NCT06835179","SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","Evaluation of the Efficacy and Safety of SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, MSS-Type, and Unresectable Metastatic Colorectal Cancer: a Single-center, Single-arm, Open-label Clinical Trail.","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender.\n* Lower edge of the lesion located ≥12 cm from the anal verge.\n* Histologically confirmed colorectal adenocarcinoma.\n* Confirmed as unresectable by multidisciplinary team (MDT) evaluation.\n* RAS mutation-positive.\n* Microsatellite\u002Fmismatch repair status: MSS\u002FpMMR.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival ≥3 months.\n* Adequate hematological, hepatic, and renal function:\n\nNeutrophil count ≥1.5 × 10⁹\u002FL; Platelet count ≥75 × 10⁹\u002FL; Serum total bilirubin ≤1.5 × upper normal limit (UNL); Aspartate aminotransferase (AST) ≤2.5 × UNL; Alanine aminotransferase (ALT) ≤2.5 × UNL; Serum creatinine ≤1.5 × UNL.\n\n* Karnofsky Performance Status (KPS) score ≥70.\n* Adequate organ function with no contraindications to surgery, radiotherapy, chemotherapy, or immunotherapy.\n* No prior chemotherapy or other antitumor therapy before enrollment.\n* No prior immunotherapy received.\n* Willingness and ability to comply with the study protocol during the trial period.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients who have received antibodies against programmed death receptor-1 (PD-1) or its ligand (PD-L1), as well as antibodies against cytotoxic T lymphocyte associated antigen 4 (CTLA-4).\n* Patients with any active autoimmune diseases or a history of requiring steroid or immunotherapy treatment.\n* Complex situations with concurrent active bleeding, perforation, or requiring emergency surgery.\n* Have received systemic anti-cancer treatment for rectal cancer.\n* Simultaneously present with other non colorectal cancer tumor diseases.\n* Patients with interstitial lung disease, non infectious pneumonia or uncontrollable systemic diseases (such as diabetes, hypertension, pulmonary fibrosis and acute pneumonia).\n* Any grade 2 or above toxic reactions (classified according to the Common Terminology Criteria for Adverse Events (CTCAE) 5th edition) caused by previous treatment that have not subsided (excluding anemia, hair loss, and skin pigmentation).\n* Pregnant or lactating women.\n* Patients who are known or have been tested for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).\n* Known or suspected history of allergies to any relevant drugs used in the trial","75 Years",{"count":57,"type":21},28,[59],"PHASE2","SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), Unresectable Metastatic Colorectal Cancer (mCRC): a Single-center, Single-arm, Open-label Clinical Trail",[62,28,63],"Unresectable Metastatic Colorectal Cancer","RAS-mutant Colorectal Cancer",[65,66,32,67,68,69,70],"SBRT","CAPEOX","PD-1 Inhibitor","RAS-Mutant","Microsatellite Stable (MSS)","Unresectable Metastatic Colorectal Cancer (mCRC)","2025-02-16",{"date":73,"type":39},"2025-02-19",{"date":75,"type":21},"2025-02",{"date":77,"type":21},"2027-05",{"name":79,"class":46},"The First Affiliated Hospital with Nanjing Medical University"]